IGF2BP1 and breast cancer: Taken together, it seems possible to draw a conclusion from these in vitro and in vivo studies that methylation events of IGF2BP1 are becoming more frequent with the higher breast cancer grade, and this leads to more silence and downregulation events of IGF2BP1, resulting in dysregulated effects on IGF2BP1-target mRNAs.